CRISPR Historical Valuation

CRSP
 Stock
  

USD 80.14  1.48  1.88%   

Some fundamental drivers such as market cap or CRISPR Therapeutics enterprice value can be analyzed from historical perspective to project value of the company into the future. Some investors analyze CRISPR Therapeutics valuation indicators such as Earnings Before Interest Taxes and Depreciation Amortization EBITDA of 428.9 M or Earnings before Tax of 409.5 M to time the market or to short-sell their positions based on the trend in valuation ratios. It is a perfect tool to project the direction of CRISPR Therapeutics's future value. Financial Statement Analysis is much more than just reviewing and breaking down CRISPR Therapeutics prevalent accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether CRISPR Therapeutics is a good buy for the upcoming year.
Continue to Trending Equities.
  

About CRISPR Valuation Data Analysis

Valuation is the financial process of determining what CRISPR Therapeutics is worth. CRISPR Therapeutics valuation ratios put that insight into the context of a company's share price, where they serve as useful tools for evaluating and utilizing investment potential. CRISPR Therapeutics valuation ratios help investors to determine whether CRISPR Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CRISPR with respect to the benefits of owning CRISPR Therapeutics security.

CRISPR Therapeutics Valuation Data Chart

CRISPR valuation ratios help to determine how cheap or expensive it is, compared to its peers or based on some benchmark measure of value for a given date. A typical valuation ratio shows the difference between the cost of CRISPR equity instrument and the benefits of owning shares of CRISPR Therapeutics AG.
CRISPR Therapeutics Invested Capital Average is very stable at the moment as compared to the past year. CRISPR Therapeutics reported last year Invested Capital Average of 1.48 Billion. As of 15th of August 2022, Tangible Asset Value is likely to grow to about 3 B, while Enterprise Value is likely to drop about 4.5 B.

Average Assets

Average asset value for the period used in calculation of Return on Average Equity and Return on Average Assets; derived from Total Assets.

Enterprise Value

Enterprise Value (or EV) is usually referred to as CRISPR Therapeutics theoretical takeover price. In the event of an acquisition, an acquirer would have to take on CRISPR Therapeutics debt, but would also pocket its cash. Enterprise Value is more accurate representation of CRISPR Therapeutics value than its market capitalization because it takes into account all of CRISPR Therapeutics AG existing debt. Enterprise value is a measure of the value of a business as a whole; calculated as Market Capitalization plus Total Debt USD minus Cash and Equivalents USD.

Market Capitalization

Market capitalization (or market cap) is the total value of the shares outstanding of CRISPR Therapeutics AG. It is equal to CRISPR Therapeutics current share price times the number of CRISPR Therapeutics outstanding shares. Represents the product of [SharesBas]; [Price] and [ShareFactor].
Most indicators from CRISPR Therapeutics valuation accounts are interrelated and interconnected. However, analyzing valuation accounts indicators one by one will only give a small insight into CRISPR Therapeutics current financial condition. On the other hand, looking into the entire matrix of valuation accounts indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Continue to Trending Equities.CRISPR Therapeutics Invested Capital Average is very stable at the moment as compared to the past year. CRISPR Therapeutics reported last year Invested Capital Average of 1.48 Billion. As of 15th of August 2022, Tangible Asset Value is likely to grow to about 3 B, while Enterprise Value is likely to drop about 4.5 B.
 2019 2020 2021 2022 (projected)
Market Capitalization3.36 B10.82 B5.8 B5.29 B
Invested Capital Average74.92 M295.1 M1.48 B1.6 B

CRISPR Therapeutics valuation accounts Correlations

CRISPR Therapeutics Account Relationship Matchups

CRISPR Therapeutics valuation accounts Accounts

201720182019202020212022 (projected)
Average Assets295.25 M433.88 M694.87 M1.34 B2.61 B2.81 B
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(63.58 M)(160.91 M)72.03 M(338.87 M)397.48 M428.86 M
Earnings Before Interest Taxes and Depreciation Amortization USD(63.58 M)(160.91 M)72.03 M(338.87 M)397.48 M428.86 M
Earnings before Tax(66.61 M)(164.43 M)67.31 M(348.06 M)379.53 M409.49 M
Average Equity194.94 M341.25 M569.7 M1.2 B2.33 B2.51 B
Enterprise Value706.46 M992.24 M2.77 B9.81 B4.98 B4.53 B
Free Cash Flow(77.91 M)(99.01 M)49.99 M(256.72 M)457.27 M493.37 M
Invested Capital13.58 M1.17 M113.14 M609.49 M1.92 B2.07 B
Invested Capital Average13.29 M5.81 M74.92 M295.1 M1.48 B1.6 B
Market Capitalization963.13 M1.48 B3.36 B10.82 B5.8 B5.29 B
Tangible Asset Value271 M488.73 M1.07 B1.83 B2.75 B2.97 B
Working Capital233.87 M438.65 M930.44 M1.62 B2.3 B2.48 B

Be your own money manager

Our tools can tell you how much better you can do entering a position in CRISPR Therapeutics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Positions Ratings Now

   

Positions Ratings

Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Module

Pair Trading with CRISPR Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CRISPR Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CRISPR Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with CRISPR Therapeutics

0.78ACLXArcellx Earnings Call  This WeekPairCorr

Moving against CRISPR Therapeutics

0.84AIMAim Immunotech Earnings Call  TodayPairCorr
0.81ABVCAbvc Biopharma Earnings Call  This WeekPairCorr
0.76ALRNAileron Therapeutics Earnings Call  TodayPairCorr
0.72ABCAmerisourcebergen Corp Fiscal Year End 3rd of November 2022 PairCorr
The ability to find closely correlated positions to CRISPR Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CRISPR Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CRISPR Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CRISPR Therapeutics AG to buy it.
The correlation of CRISPR Therapeutics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CRISPR Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CRISPR Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CRISPR Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Trending Equities. Note that the CRISPR Therapeutics information on this page should be used as a complementary analysis to other CRISPR Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Complementary Tools for CRISPR Stock analysis

When running CRISPR Therapeutics price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Is CRISPR Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CRISPR Therapeutics. If investors know CRISPR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CRISPR Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
6.1 B
Quarterly Revenue Growth YOY
-1.0
Return On Assets
-0.15
Return On Equity
-0.27
The market value of CRISPR Therapeutics is measured differently than its book value, which is the value of CRISPR that is recorded on the company's balance sheet. Investors also form their own opinion of CRISPR Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CRISPR Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CRISPR Therapeutics' market value can be influenced by many factors that don't directly affect CRISPR Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CRISPR Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine CRISPR Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CRISPR Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.